The Alzheimer’s Blood Test Performance Database
As blood test innovations for Alzheimer’s disease accelerate, understanding how each test performs is essential to making evidence-based decisions for patient care. This database demonstrates how available blood tests compare to CEOi’s published standards.
Explore How Each Test Compares
This page will be updated as new data is submitted
Fujirebio: Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio
pTau 217/β-Amyloid 1-42 Ratio
ARUP Laboratories: Phosphorylated tau 217a
p-tau217
Neurocode: p-Tau217a
p-tau217
C2N Diagnostics: PrecivityAD®
Aß42/40 Ratio, ApoE and Age
C2N Diagnostics: PrecivityAD2™
Aß42/40 Ratio and p-Tau217/np-Tau217 Ratio
Quest Diagnostics: Aβ 42/40, p-tau217, and ApoE Evaluation
Aβ 42/40, p-Tau217, and ApoE Evaluation
Quest Diagnostics: AD-Detect™ (Aβ 42/40 and p-tau217)
Aβ 42/40 and p-Tau217
Quest Diagnostics: AD-Detect™ Phosphorylated tau217
p-Tau217
Quest Diagnostics: AD-Detect™ Beta-Amyloid 42/40 Ratio
Aβ 42/40
Lucent Diagnostics: LucentAD
p-Tau 217
Lucent Diagnostics: LucentAD Complete
p-Tau 217, Aβ42/40, NfL, and GFAP
Mayo Clinic Laboratories: p-Tau217
p-Tau217
CEOi’s Approach to Compiling the Database
Data Submission
CEOi engaged companies with available blood tests for Alzheimer’s disease in the US, requesting they complete a standardized data table and provide a publicly available source to support the submitted information.
Quality Check
Once data submissions were received, CEOi conducted an independent quality check. Each dataset in the database is clearly labeled with its source.
Study Population
Only data from cognitively impaired individuals are included in the database. If data have been adjusted to exclude cognitively unimpaired participants, this is clearly noted in the respective data table.
Contact Us
If you are interested in submitting your data to the Performance Standards Database, or have questions or comments on the existing data, please complete this form.
The Global CEO Initiative on Alzheimer’s Disease
CEOi, founded in 2013, is an organization of private-sector leaders who have joined together to provide business leadership in the fight against Alzheimer’s. CEOi believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges. It is convened by UsAgainstAlzheimer’s.
